Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026
24.08.2026 08:35
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention
20.08.2026 10:51
Decent Value screen flags Alnylam Pharmaceuticals (ALNY) for strong growth, solid profitability, and reasonable forward valuation.
American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
11.08.2026 09:30
U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
06.08.2026 12:30
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Alnylam (ALNY) Q2 2026 Earnings Call Transcript
04.08.2026 01:54
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
Alnylam (ALNY) Q2 2026 Earnings Call Transcript
04.08.2026 01:54
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450
03.08.2026 06:49
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $527 to $450.
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation
01.08.2026 09:40
Alnylam Pharmaceuticals (ALNY) combines strong growth with reasonable valuation, making it an affordable growth stock. See why its metrics stand out.
US Stock Market Today: S&P 500 Futures Inch Higher As Inflation Data Looms
31.07.2026 08:09
The Morning Bull - US Market Morning Update Friday, Jul, 31 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.3% and Nasdaq-100 futures ahead roughly 0.5%. The focus is on the June US PCE price index, which is expected to dip 0.1% month on month, while the core reading is seen up 0.2%. That combination suggests the cost of living may be easing slowly but still sits above the Federal Reserve's 2% goal. At the same time, second quarter US GDP is...
Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
31.07.2026 03:20
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
Why Alnylam’s Best Quarter Ever Didn’t Come With a Richer Valuation
28.07.2026 08:16
2026 has marked a significant turning point in biotech capital markets, not just a small comeback. Venture funding for biotech startups reached $9.1 billion in the first half of the year, the highest first-half total since 2022, while 13 biotech IPOs raised a combined $4.5 billion, with a median haul of nearly $302 million per […]
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
27.07.2026 14:00
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
21.07.2026 16:28
Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.The definitive benchmark for biomarker dealmaking Biomarker partnering is driven by data, discovery, and precisi
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth
17.07.2026 08:10
Alnylam Pharmaceuticals (ALNY) offers strong value in biotech with a P/E below 90% of peers, rapid earnings growth of 288%, and high profit margins, despite moderate debt.
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
16.07.2026 05:44
Alnylam's robust cash position and GAAP profitability materially reduce investment risk and support pipeline development. Learn why ALNY stock is a buy.
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
15.07.2026 12:54
AstraZeneca PLC Q2 2026 preview: revenue growth, Enhertu sales surge and EU approval, plus risk/reward after Wainua trial setback. Click for this AZN stock update.
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
15.07.2026 07:30
CAMBRIDGE, Mass., July 15, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases.
Alnylam Highlights Neuroscience Progress At AAIC 2026, Initiating Phase 2 APPlauDS Study Of Mivelsiran In Down Syndrome-Associated Alzheimer's While Completing cAPPricorn-1 Enrollment In CAA
15.07.2026 03:48
− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid
Amyloidosis Continues To Fight Back
14.07.2026 09:55
AstraZeneca and its partners at Ionis have been working on an antisense oligonucleotide therapy (eplontersen) to slow progression of transthyretin-mediated amyloidosis. That failed recently.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock
14.07.2026 08:40
Louis Navellier's strategy identifies high-potential stocks with eight fundamental rules, and Alnylam Pharmaceuticals (ALNY) perfectly fits the screen with 82.57% revenue growth, 443% EPS growth, and accelerating momentum.